



(51) International Patent Classification:

C07D 413/14 (2006.01) *A61K 31/506* (2006.01)
C07D 417/14 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/IB2013/060052

(22) International Filing Date:

11 November 2013 (11.11.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/725,113 12 November 2012 (12.11.2012) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **FAIRHURST, Robin Alec** [GB/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **FURET, Pascal** [FR/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **KALTHOFF, Frank Stephan** [DE/AT]; Novartis Pharma GmbH, Dermatology, Muthgasse 11/2, A-1190 Wien (AT). **LERCHNER, Andreas** [CH/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH). **RUEEGER, Heinrich** [CH/CH]; Novartis Pharma AG, Werk Klybeck, Postfach, CH-4002 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES

(57) Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.



WO 2014/072956 A1